Search results

1

Problems of anticoagulant therapy in elderly cancer patients with atrial fibrillation and hemorrhagic stroke

100%

Ballyuzek M. F., Mashkova M. V.

OncoReview

|

2017

|

vol. 7

|

issue 4

168-170

EN

The problems of antithrombotic and first of all, anticoagulant therapy in patients with concomitant oncological and cardiovascular pathology, especially in gerontological practice, remain to be unsolved. The need to use anticoagulants is dictated by a high risk of thromboembolism in cancer patients combined with age-associated atrial fibrillation. The risk of hemorrhage increases with the age; moreover, there is a risk of dangerous drug interactions due to the need of polymorbid pathology treatment. Thus, the clinical situation sometimes creates difficulties in choosing a proper tactic in patient management and following the existing treatment standards. A clinical case of a patient of an elder age with the recurrence of lung cancer, which has an established high-risk of thromboembolism, and with paroxysmal form of atrial fibrillation and new oral anticoagulants treatment, is considered.

2

Cardiooncological balance in a 75-year-old male with a hepatocellular carcinoma CS IV and a congestive heart failure NYHA III „de novo”

100%

Żechowicz M., Wroński K., Rucińska M.

OncoReview

|

2015

|

vol. 5

|

issue 2

A57-61

EN

The case reports about a 75-years-old man without a previous medical history, in whom a heart failure NYHA III de novo was diagnosed together with persistent atrial fibrillation and hepatocellular carcinoma in clinical stage IV. Based on echocardiography and computed tomography there were pulmonary hypertension in course of lymphangiosis carcinomatosa as well as diffuse metastases in the abdomen diagnosed. Before the treatment initiation the patient was classified 3 in WHO performance status. After an improvement in control of the rhythm frequency and the heart failure treatment stabilisation with a β-blocker, an ACE-inhibitor, spironolactone and furosemide, the patient’s performance status improved to WHO 2. He was further disqualified from surgical procedures due to the advanced clinical stage of the oncological disease. Considering high probability of further cardiotoxic influence of sorafenib on the heart failure despite its satisfactory control, the patient was assigned to palliative chemotherapy with FOLFOX. Parallel he was strictly followed up cardiologically in an outpatient clinic what certainly supported the oncological treatment. The patient survived 32 weeks from the first hospitalization and the progression free survival was 12 weeks from the chemotherapy initiation.

3

Cardiotoxicity of antiangiogenic drugs: causes and mechanisms

88%

Tomaszewska B., Muzolf M., Grabysa R., Bodnar L.

OncoReview

|

2021

|

vol. 11

|

issue 1

12-18

EN

Therapy with angiogenesis inhibitors is undoubtedly an advancement in cancer treatment; however, it is associated with a risk of developing cardiotoxicity, which most often manifests in myocardial contractile dysfunction or an increased risk of thromboembolic events. Heart failure is observed in 2–4% of patients treated with bevacizumab and in 3–8% of patients on antiangiogenic tyrosine kinase inhibitors. The proposed pathomechanisms underlying the impairment in systolic function during antiangiogenic drug treatment include mitochondrial dysfunction, a secondary reduction in cardiomyocyte ATP production and redox imbalance, which may contribute to pathological states known as “free radical diseases”. Additionally, therapy with angiogenesis inhibitors may also cause cardiac oxidative stress. The risk factors for cardiac complications include arterial hypertension, which is a known “class effect” of this class of drugs, as well as a number of other factors such as age, comorbidities, prior radiotherapy and baseline left ventricular ejection fraction. The cardiovascular diseases are still the first cause of death in the world. The more effective oncological treatment becomes, the more often comorbidities occur. This fact seems to demand interdisciplinary approach from investigators and practitioners. This article presents the current state of knowledge on the molecular mechanisms of cardiotoxicity of antiangiogenic drugs used in routine clinical practice.

4

The oncological treatment and cardiotoxicity problem – the role of biomarkers

88%

Dudek M., Kałużna-Oleksy M., Migaj J., Lesiak M., Straburzyńska-Migaj E.

OncoReview

|

2020

|

vol. 10

|

issue 4

130-133

EN

Cancer and cardiovascular diseases are a leading causes of morbidity and mortality in developed countries. Cardiological complications of oncological treatment are a significant problem that can be manifested in both permanent and transient cardiac dysfunction including myocardial damage, left ventricular dysfunction, and heart failure, hypertension, ischemia, as well as arrhythmias or QT prolongation, which can be life-threatening. Early detection of cardiotoxicity due to cancer treatment is crucial in the prevention of adverse cardiovascular outcomes in this group of patients. In this review we try to summarize the role of biomarkers in the detection of cardiotoxicity due to cancer treatment.

5

Typical variant of takotsubo cardiomyopathy in oncological patients. Two case reports and review of the literature

75%

Stępień K., Nowak K., Pasieka P., Warmuz K., Stępień A., Nessler J., Zalewski J., Stępień K., Nowak K., Pasieka P., Warmuz K., Stępień A., Nessler J., Zalewski J.

Folia Medica Cracoviensia

|

2020

|

vol. 60

|

issue 1

Refine search results

4 OncoReview

1 Folia Medica Cracoviensia

1 2021

2 2020

1 2017

1 2015

1 Ballyuzek M. F.

1 Bodnar L.

1 Dudek M.

1 Grabysa R.

1 Kałużna-Oleksy M.

1 Lesiak M.

1 Mashkova M. V.

1 Migaj J.

1 Muzolf M.

1 Nessler J.

1 Nowak K.

1 Pasieka P.

1 Rucińska M.

1 Straburzyńska-Migaj E.

1 Stępień A.

1 Stępień K.

1 Tomaszewska B.

1 Warmuz K.

1 Wroński K.

1 Zalewski J.

1 Żechowicz M.

Problems of anticoagulant therapy in elderly cancer patients with atrial fibrillation and hemorrhagic stroke

Cardiooncological balance in a 75-year-old male with a hepatocellular carcinoma CS IV and a congestive heart failure NYHA III „de novo”

Cardiotoxicity of antiangiogenic drugs: causes and mechanisms

The oncological treatment and cardiotoxicity problem – the role of biomarkers

Typical variant of takotsubo cardiomyopathy in oncological patients. Two case reports and review of the literature